Clinical Trial Update: Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) [Phase 1]

View source ↗

Summary

The Phase 1 trial of Frespaciguat (MK-5475) in participants with hypoxemia due to COVID-19 pneumonia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoxemia
• Pneumonia

Drugs mentioned

• Frespaciguat

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Coronavirus Disease 2019 (COVID-19), Pneumonia | Phase 1 | Status: WITHDRAWN